James Kennedy

James Kennedy is an Associate Professor of Geratology & Stroke Medicine at the University of Oxford's Radcliffe Department of Medicine. His research focuses on stroke outcomes, biomarkers, and clinical trials in stroke medicine. He is involved in studies such as the TEMPO-2 trial and the NIMBLE study, investigating treatment efficacy and predictive biomarkers for stroke patients.

His research interests include the application of biomarkers like neuron-specific enolase and S100B protein to predict stroke outcomes, as well as the evaluation of endovascular treatments and cerebral embolic protection in cardiovascular procedures. He explores gender differences in stroke recovery and the role of thrombolytic agents such as tenecteplase in minor stroke management.

Recent publications highlight his contributions to understanding stroke treatment efficacy and biomarker development. His work spans both clinical trials and preliminary studies, emphasizing translational research in acute stroke management and cardiovascular interventions.

No scientific awards are listed in the available information. Advising and grants: No advisees or grant information is provided in the text. His research collaborations include contributions to the TEMPO-2 and NIMBLE studies.

His work is conducted within the Radcliffe Department of Medicine, focusing on investigative medicine and stroke-related research, aligned with the department’s broader goals in clinical and translational science.